NCAM1 and adenoma: Focusing on the promoter methylation status of the neuroendocrine markers chromogranin A (CgA), chromogranin B (CgB) and CD56 (NCAM1) confirmed congruently lower methylation levels in NETs and PitNETs/adenomas compared to adenomas (Fig. 3C).